OMGAQ (Omega Therapeutics) ROCE %: -48.43% (As of Sep. 2024)


OMGAQ Omega Therapeutics Inc OMGAQ
16 GF Score
Price $0.00
View Full Analysis

What is Omega Therapeutics ROCE %?

Omega Therapeutics OMGAQ +50.00% 16 ROCE % is -48.43% as of Sep. 2024. GuruFocus rates OMGAQ with a GF Score™ of 16/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Omega Therapeutics's annualized ROCE % for the quarter that ended in Sep. 2024 was -48.43%.

Omega Therapeutics  (OTCPK:OMGAQ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Omega Therapeutics ROCE % Related Terms

Omega Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Omega Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Omega Therapeutics ROCE % Chart

Omega Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROCE %
-445.67 -236.19 -54.63 -59.51 -66.49

Omega Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.42 -44.93 -48.61 -43.97 -48.43
OMGAQ
16GF Score
Omega Therapeutics Inc OMGAQ
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Omega Therapeutics ROCE % Calculation

Omega Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-100.261/( ( (145.998 - 21.964) + (204.366 - 26.806) )/ 2 )
=-100.261/( (124.034+177.56)/ 2 )
=-100.261/150.797
=-66.49 %

Omega Therapeutics's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=-65.68/( ( (168.225 - 25.543) + (152.727 - 24.173) )/ 2 )
=-65.68/( ( 142.682 + 128.554 )/ 2 )
=-65.68/135.618
=-48.43 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -48.43% mean?
Omega Therapeutics (OMGAQ) has a ROCE % of -48.43% as of Sep. 2024.
Is Omega Therapeutics' ROCE % too high?
Omega Therapeutics' current ROCE % is -48.43%. Overall, Omega Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Omega Therapeutics' ROCE % compare to ENDV and ORGS?
Omega Therapeutics' ROCE % of -48.43% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Omega Therapeutics's current ROCE % is -48.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omega Therapeutics stock overvalued right now?
Omega Therapeutics (OMGAQ) has a current ROCE % of -48.43%. The current ROCE % is -48.43%. Omega Therapeutics' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Omega Therapeutics (OMGAQ), the current ROCE % is -48.43% as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Omega Therapeutics Business Description

Address 140 First Street, Suite 501, Cambridge, MA, USA, 02141
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.
16GF Score

Get the complete analysis for OMGAQ

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price